Breaking News

WuXi Biologics to Acquire CMAB Biopharma Group

Will increase 7000L drug substance capacity (MFG21) and drug product capacity (DP11) for liquid and lyophilization within its global manufacturing network.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

WuXi Biologics entered into a purchase agreement with CBC Group, a healthcare-dedicated investment firm, and other companies including Ming Bioventures under which WuXi Bio will acquire over 90% interest of CMAB Biopharma Group. The transaction is expected to close 2Q21.   CMAB is a CDMO based in Suzhou, China, providing services from cell-line development, process development to clinical GMP manufacturing and has over 250 employees. Upon transaction completion, WuXi Biologics will increase 70...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters